<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_HAFS_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:HAFS/Description</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P>﻿
</P><H1 class="logo">iGEM HAFS</H1><NAV class="menu"><UL><LI><A href="#">PROJECT ▾</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Description">Description</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Applied_Design">Design</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Model">Model</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Results">Results</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Improve">Parts</A></LI></UL><LI><A href="#">HUMAN PRACTICES ▾</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Human_Practices">Human Practices</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Public_Engagement">Engagement</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/InterLab">INTERLAB</A></LI><LI><A href="#">TEAM ▾</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Team">Team</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Attributions">Attributions</A></LI><LI><A href="https://2018.igem.org/Team:HAFS/Collaborations">Collaborations</A></LI></NAV><DIV id="title"><P style="font-size:5em; color: #6C5B7B; text-align: center; font-family: 'Quicksand', sans-serif; font-weight: bold; padding:0; margin:0">Project Description</P></DIV><H2 class="title-conteudo"> Project Summary </H2><DIV class="conteudo"><DIV style="padding:3%">

This year, our project was to develop a synthetic biology based oral delivery method for insulin to treat both type 1 and 2 diabetes mellitus. We aimed to engineer non propagating bacterial minicells to deliver insulin analog that can be absorbed by the intestinal epithelium. This system would eliminate the need to use invasive needles to inject insulin everyday. Our method is not only easier and faster but also considerably safe, since the minicells don't propagate and will be safely removed after achieving their goals. The figure below further elaborates on the workings of the <I> E. coli </I> couriers. 
</DIV></DIV><P><TITLE>Team: AQA_Unesp</TITLE></P><DIV id="footer"><DIV id="contact" class="btm_box"><P>
			Hankuk Academy of Foreign Studies 
			International studies
			Gyeong gi, South Korea
			kyuhee0622@gmail.com</P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>